BCL2 and non-Hodgkin lymphoma: Our results align with previous work showing that normal lymphoid cell and human non-Hodgkin lymphoma resistance to ABT-737 is conferred by mutant BIM specific for BCL-2, BCL-XL, and BCL-W [28].